FLT3 antibody-based therapeutics for leukemia therapy (Q36251188)

13 August 2017

1 reference

title

FLT3 antibody-based therapeutics for leukemia therapy (English)

1 reference

13 August 2017

Yiwen Li

1

1 reference

13 August 2017

Zhenping Zhu

series ordinal

2

1 reference

13 August 2017

publication date

1 August 2005

1 reference

International Journal of Hematology

13 August 2017

published in

1 reference

13 August 2017

volume

82

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

108-114

1 reference

Mylotarg: antibody-targeted chemotherapy comes of age.

13 August 2017

cites work

1 reference

12 December 2020

Antibodies have the intrinsic capacity to destroy antigens

1 reference

12 December 2020

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

12 December 2020

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

1 reference

12 December 2020

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

12 December 2020

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy

1 reference

12 December 2020

Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Improving the efficacy of antibody-based cancer therapies

1 reference

12 December 2020

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

12 December 2020

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen

1 reference

12 December 2020

Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

1 reference

12 December 2020

Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells

1 reference

12 December 2020

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

12 December 2020

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies

1 reference

12 December 2020

Production of monoclonal antibodies in COS and CHO cells

1 reference

12 December 2020

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

12 December 2020

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia

1 reference

12 December 2020

Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment.

1 reference

12 December 2020

Bi-specific antibody therapy for the treatment of cancer.

1 reference

12 December 2020

Clinical trials of antibody therapy

1 reference

12 December 2020

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

12 December 2020

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

12 December 2020

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

1 reference

12 December 2020

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

12 December 2020

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

12 December 2020

The roles of FLT3 in hematopoiesis and leukemia

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

1 reference

12 December 2020

Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

1 reference

12 December 2020

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

1 reference

12 December 2020

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia

1 reference

12 December 2020

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice

1 reference

12 December 2020

Small molecule FLT3 tyrosine kinase inhibitors

1 reference

12 December 2020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

12 December 2020

Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

12 December 2020

Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma

1 reference

12 December 2020

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo

1 reference

12 December 2020

Of mice and men: hybridoma and recombinant antibodies

1 reference

12 December 2020

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Progress in immunoconjugate cancer therapeutics

1 reference

12 December 2020

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

1 reference

12 December 2020

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

1 reference

12 December 2020

Bexxar (Corixa/GlaxoSmithKline).

1 reference

12 December 2020

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

12 December 2020

Bispecific antibody conjugates in therapeutics

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.05068

1 reference

Dimensions Publication ID

13 August 2017

1027116935

0 references

1 reference